<DOC>
	<DOC>NCT00091715</DOC>
	<brief_summary>The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.</brief_summary>
	<brief_title>Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>PAH NYHA Class II Significant elevation of mean pulmonary arterial pressure Significant elevation of pulmonary vascular resistance at rest Limited 6minute walk distance PAH secondary to portal hypertension, complex congenital heart disease or reverse shunt Restrictive or obstructive lung disease Significant vasoreactivity Treatments for PAH (within 4 weeks of randomization)</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>PAH</keyword>
	<keyword>PPH</keyword>
	<keyword>bosentan</keyword>
	<keyword>early</keyword>
</DOC>